Reven Pharmaceuticals
Manufacturing · Colorado, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2921 W 120th Ave Unit 220, Westminster, ...Phone Number
(720) 618-0658Website
www.reven.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Reven Pharmaceuticals
Reven Pharmaceuticals is dedicated to advancing scientific innovation to enhance health and well-being through a new generation of pharmacological solutions. The company focuses on restoring immune system homeostasis to address the root causes of diseases, particularly those related to inflammation, such as cancer and cardiovascular conditions. Their proprietary RJX technology offers a flexible formulation that targets immunologic functions without stabilizers or preservatives. Reven aims to significantly impact the healthcare landscape, similar to the historical impact of antibiotics on infectious diseases.Explore more
Reven Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Reven Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Reven Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Reven Pharmaceuticals
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Reven Pharmaceuticals launches new products
Earning: See what the market has to say on Reven Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Reven Pharmaceuticals had a recent Job posting/layoffs
Check if Reven Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Reven Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Reven Pharmaceuticals has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Reven Pharmaceuticals
Compare insights from companies similar to Reven Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Reven Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Reven Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Reven Pharmaceuticals.
Reven Pharmaceuticals financials insights
Gather financial insights about Reven Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Debt
$1.8M
2014
Private Equity
$4.4M
Reven Pharmaceuticals Tech Stack
A closer look at the technologies used by Reven Pharmaceuticals
Reven Pharmaceuticals News & Media
Reven Holdings Announces First Patient Dosed in Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients
WESTMINSTER, Colo.--(BUSINESS WIRE)--"We are expecting topline data from this very important study by end of 2021,” said Brian Denomme, Reven’s President.Reven Holdings Announces Successful Completion of the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients
WESTMINSTER, Colo.--(BUSINESS WIRE)--REVEN SUCCESSFULLY COMPLETES PART 1 OF THE RANDOMIZED COVID-19 STUDY EVALUATING ITS LEAD ANTI-SEPSIS DRUG CANDIDATE RJXReven’s Co-Founder Michael Volk Appears on Cheddar News
WESTMINSTER, Colo.--(BUSINESS WIRE)--Reven Holdings, Inc. (“Reven”), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses—including COVID-19—and inflammatory disorders, yesterday co-founder Michael Volk appeared on Cheddar News (40 million pay-tv households) to discuss the future of medicine. In this national broadcasted interview, Mr. Volt shared the company’s goals to bringReven Pharmaceuticals Reports a Promising Second Generation Formulation of Its Lead Anti-sepsis Drug Candidate Rejuveinix (RJX)
WESTMINSTER, Colo.--(BUSINESS WIRE)--Reven Team publishes a new peer-reviewed paper on a novel formulation of its proprietary anti-sepsis drug candidate RJX.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Reven Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Reven Pharmaceuticals is dedicated to advancing scientific innovation to enhance health and well-being through a new generation of pharmacological solutions. The company focuses on restoring immune system homeostasis to address the root causes of diseases, particularly those related to inflammation, such as cancer and cardiovascular conditions. The... Read More
